Agile SEC filing reveals FDA rejection for Twirla contraceptive

Hidden deep inside a 17 March S-1 filing with the Securities and Exchange Commission (SEC) was the disclosure from Agile Therapeutics it had received a complete response letter (CRL) from the FDA for the firm's experimental once-weekly, low-dose contraceptive patch Twirla (AG200-15).